Table 3.
Frequency and Percentage of ER, PR, Her2/neu Expression in BRCA1(+ve) and BRCA1(-ve) Cases
| BRCA11 (+) No. (%) |
BRCA1 (-) No. (%) |
Total No. (%) |
p-
value |
|
|---|---|---|---|---|
| Oestrogen Receptors (ERs) | ||||
| ER2 + | 2 (28.5) | 19 (33.9) | 21 (33.33) | >0.05 |
| ER - | 5 (71.4) | 37 (66.07) | 42 (66.66) | |
| Total | 7 (100.0) | 56 (100.0) | 63 (100.0) | |
| Progesterone Receptors (PRs) | ||||
| PR3 + | 3 (42.85) | 23 (41.07) | 25 (39.6) | >0.05 |
| PR - | 4 (57.15) | 33 (58.93) | 38 (60.4) | |
| Total | 7 (100.0) | 56 (100.0) | 63 (100.0) | |
| Her2/neu Receptors | ||||
| Her2/neu4 + | 4 (40) | 8 (36.36) | 12 (37.5) | >0.05 |
| Her2/neu - | 6 (60) | 14 (63.63) | 20 (62.5) | |
| Total | 10 (100.0) | 22 (100.0) | 32 (100.0) | |
1, BRCA1 denotes to breast cancer susceptibility type 1; 2, ER denotes to oestrogen receptors; 3, PR denotes to progesterone receptors; 4, Her2/neu denotes to human epidermal growth factor receptor 2.